TY - JOUR
T1 - Usage of HCV viremic organs in liver transplantation to anti-HCV negative recipients
T2 - The current status and review of literature
AU - Örmeci, Asli Çiftçibaşi
AU - Yildiz, Çaǧla
AU - Saberi, Behnam
AU - Gürakar, Merve
AU - Şimşek, Cem
AU - Gürakar, Ahmet
N1 - Publisher Copyright:
© 2019 AVES. All rights reserved.
PY - 2019
Y1 - 2019
N2 - Liver transplantation is the main curative therapy for end-stage liver disease. The number of transplanted organs is increasing globally. However, the number of available organs in the pool is insufficient, considering the excessive number of patients on the waiting list, which is a major concern for transplant programs. Hepatitis C infection (HCV) is a common indication for liver transplantation, and in recent years, a major progress has been made in its treatment with direct-acting antiviral (DAA) agents. HCV-positive livers have been transplanted to HCV-positive recipients for a long time. The high rate of sustained virologic response through DAA has brought new treatment options for the patients during the pre- and post-transplantation periods. Recently, there have been few reports of transplanting the available HCV-positive organs to HCV noninfected recipients. However, there is not yet an agreement on the optimal selection of patients who would benefit from such transplantation, and this has become a current topic of interest. Thus, we aim to review the current literature on this evolving topic.
AB - Liver transplantation is the main curative therapy for end-stage liver disease. The number of transplanted organs is increasing globally. However, the number of available organs in the pool is insufficient, considering the excessive number of patients on the waiting list, which is a major concern for transplant programs. Hepatitis C infection (HCV) is a common indication for liver transplantation, and in recent years, a major progress has been made in its treatment with direct-acting antiviral (DAA) agents. HCV-positive livers have been transplanted to HCV-positive recipients for a long time. The high rate of sustained virologic response through DAA has brought new treatment options for the patients during the pre- and post-transplantation periods. Recently, there have been few reports of transplanting the available HCV-positive organs to HCV noninfected recipients. However, there is not yet an agreement on the optimal selection of patients who would benefit from such transplantation, and this has become a current topic of interest. Thus, we aim to review the current literature on this evolving topic.
KW - Hepatitis C virus
KW - Increased-risk donor
KW - Nucleic acid test
KW - Transmission infection
KW - Transplantation
KW - Viremic donors
UR - http://www.scopus.com/inward/record.url?scp=85072278962&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072278962&partnerID=8YFLogxK
U2 - 10.5152/tjg.2019.18656
DO - 10.5152/tjg.2019.18656
M3 - Review article
C2 - 31530520
AN - SCOPUS:85072278962
SN - 1300-4948
VL - 30
SP - 771
EP - 775
JO - Turkish Journal of Gastroenterology
JF - Turkish Journal of Gastroenterology
IS - 9
ER -